| Company/Division name | Nobelpharma America, LLC |
| Parent company | Nobelpharma Co., Ltd. |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 20 |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2020 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Bethesda |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Regulatory compliance |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Proximity to customers/market, proximity to NIH and regulators |
